Put company on watchlist
Marinomed Biotech AG
ISIN: ATMARINOMED6
WKN: A2N9MM
About
Company Snapshot
New: Activate notification
Be informed about new publications
New: AI Factsheet

Coming soon: Summary of the company message by AI/p>

Marinomed Biotech AG · ISIN: ATMARINOMED6 · Newswire (Company)
Country: Österreich · Primary market: Austria · EQS NID: 2151616
06 June 2025 15:20PM

Marinomed Biotech AG announces partnership for Budesolv in Switzerland


EQS-News: Marinomed Biotech AG / Key word(s): Alliance
Marinomed Biotech AG announces partnership for Budesolv in Switzerland

06.06.2025 / 15:20 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

Marinomed Biotech AG announces partnership for Budesolv in Switzerland

 

 

  • Marinomed has signed a binding term sheet with a Swiss pharma partner for the development and marketing of Budesolv for the Swiss market
  • With this Marinomed is eligible to receive milestone payments and royalties
  • Switzerland to serve as a reference country for certain markets abroad

 

Korneuburg, Austria, June 6th , 2025 - Marinomed Biotech AG (VSE:MARI) announces that it has signed a binding term sheet with a Swiss pharmaceutical company for the development and marketing of Budesolv for the Swiss market. The new partner has been granted exclusive rights to sell and distribute Budesolv under its own brand. The deal includes the final development steps that are necessary for filing the marketing authorization in Switzerland. Marinomed is eligible to receive undisclosed upfront and milestone payments as well as royalties on sales. Marinomed retains all rights outside the territory and has the right to use the dossier compiled for Switzerland outside the territory.

 

“This is an important step for Marinomed and Budesolv. Following the encouraging communication with Swissmedic we are excited to develop this project to the next level. We have found the perfect partner for registration and the first launch of Budesolv”. Andreas Grassauer, CEO of Marinomed, mentions. “We are confident that this deal is the first trigger for several other partnerships to come. We are convinced that a registration in Switzerland will enable opportunities in a series of other markets abroad.”

 

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.

 

For further inquiries contact:

Marinomed Biotech AG
PR: Luca Horinek
IR.: Tobias Meister
T: +43 2262 90300 158
E-Mail: pr@marinomed.com
E-Mail: ir@marinomed.com
 

 

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.

 



06.06.2025 CET/CEST This Corporate News was distributed by EQS Group. www.eqs.com


Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market)
EQS News ID: 2151616

 
End of News EQS News Service

2151616  06.06.2025 CET/CEST

smart.AD

Trading Solutions for Professionals

  • 25 kinds of clusters
  • 26 world exchanges
  • 14 different charts
  • 58 necessary for analysis indicators
  • 50+ customized templates for charts


Get your free Demo today

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Saturday, 07.06.2025, Calendar Week 23, 158th day of the year, 207 days remaining until EoY.